China Pharma Holdings (CPHI) announced that through Hainan Helpson Medical and Biotechnology Co., a wholly owned subsidiary, it expects to launch Dry Eye Disease Therapeutic Device in the first quarter of 2025 in China. It is a medical treatment device for dry eye disease under patent protection. The company, through Helpson, acquired the technology at the end of 2022.
China Pharma Holdings is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.